研究業績 (2016年1月～12月)
英文原著論文
1. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population. Kitagawa F, Ishii J, Hiramitsu S, Takahashi H, Okuyama R, Kawai H, Muramatsu T, Harada M, Motoyama S, Naruse H, Matsui S, Sarai M, Hayashi M, Watanabe E, Izawa H, Ozaki Y.Heart Vessels. 2016 Oct 28.
2. Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.Furuhashi M, Matsumoto M, Hiramitsu S, Omori A, Tanaka M, Moniwa N, Yoshida H, Ishii J, Miura T. PLoS One. 2016 Apr 28;11(4):e0154482. doi: 10.1371/journal.pone.0154482.
3. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai N, Tokutake E, Uchiyama K, Sugawara M, Kakuda H, Wakasa Y, Mori H, Hisatome I, Waki M, Ohya Y, Kimura K, Saito Y; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators..
4. Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. Furuhashi M, Hiramitsu S, Mita T, Omori A, Fuseya T, Ishimura S, Watanabe Y, Hoshina K, Matsumoto M, Tanaka M, Moniwa N, Yoshida H, Ishii J, Miura T. Lipids Health Dis. 2016 Jan 12;15:5. doi: 10.1186/s12944-016-0177-8.